Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy
Goran Kungulovski, Marija Gjorgjievska, Sanja Mehandziska, Djansel Bukovec, Milan Risteski, Ivan Kungulovski, Zan Mitrev
This study shows that tumors with chromatin regulator mutations have higher mutational burden and better response to immunotherapy.
medRxiv · Oct 15, 2024 · PreprintGenetic & Genomic Medicine